Sramana Mitra: All these areas that we are talking about are talent war scenarios. They are highly-specialized areas. There’s not an abundance of people who have great expertise. That’s another driver for these acquisition scenarios. The larger companies are also trying to hire talent. One of the ways they hire talent is by acquiring smaller
Sramana Mitra: We have very aggressively developed a whole track within our program. We have a big education effort. We are scaling that with some very interesting partnerships including with Udemy. The theme that we have developed around this topic is Bootstrapping to Exit. By bootstrapping, I don’t only mean companies that are working without
Sramana Mitra: You started off by saying that you’ve already had seven exits within three years. Talk to me a little bit more about the exit. What are the circumstances of these? That’s unusual for a small micro-VC to have seven exits within a three-year period. Warren Weiss: One of the areas that we’re in
Warren Weiss is Managing Partner at WestWave Capital. We had a terrific discussion on small exits as seen by a seasoned investor. Sramana Mitra: Warren is very well-known in the industry as “Bunny Weiss”. That’s his nickname. I’ve known him for a very long time. He was a General Partner at Foundation Capital for many
Ben Narasin: You build your business up to $5 million in revenue. It seems like a healthy lifestyle business to me. If you have a 40% gross margin, that means $2 million is flowing to you. If you can keep your operational expenses low, that can be a great living. Later, there are people who
Sramana Mitra: The most important thing is that big market opportunity. Hypergrowth is not a natural state of business. If every entrepreneur thinks that we have to achieve hypergrowth, that is not viable. Most businesses don’t have the characteristics of being able to meet that hypergrowth criteria. Ben Narasin: Absolutely agree. Venture wasn’t built to
Sramana Mitra: When it comes to some of the patient monitoring stuff, which is a very active category, all applications of information technology, especially the AI algorithm in drug discovery, how do you view the role of FDA or an equivalent regulatory body? Rajeev Singh-Morales: I’ll be very candid. I’m not an expert on FDA
Sramana Mitra: What trends do you see in your deal flow? Rajeev Singh-Morales: We are a fund that is mostly B2B. We don’t a have an industry focus. There are certain areas in pharma and biotech which are extraordinarily hot right now. We don’t invest in that. We do invest in digital health. That is